Labiana Health

Labiana Health Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Labiana Health (LAB.MC) as of Nov 19, 2026 is 8.34. In the previous year, Cash Conversion Cycle (CCC) was 69.31 — a change of -87.96% (lower).

Cash Conversion Cycle

8.34

YoY

-87.96%

Last updated:

Cash Conversion Cycle (CCC) of Labiana Health is 2025 8.34 . Cash Conversion Cycle (CCC) of Labiana Health was 2024 69.31 . It decreases by -87.96% lower compared to the previous year.

The Labiana Health Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
161.87 EUR
Jan 1, 2019
198.63 EUR
Jan 1, 2021
107.14 EUR
Jan 1, 2022
91.44 EUR
Jan 1, 2023
109.29 EUR
Jan 1, 2024
69.31 EUR
Jan 1, 2025
8.34 EUR
The Labiana Health Cash Conversion Cycle history
YEARCash Conversion CycleYoY
8.34-87.96%
69.31-36.59%
109.29+19.52%
91.44-14.66%
107.14-46.06%
198.63+22.71%
161.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Cash Conversion Cycle (CCC) of Labiana Health is 8.34 in 2025.

Cash Conversion Cycle (CCC) of Labiana Health changed from 69.31 to 8.34, representing a -87.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Labiana Health since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Labiana Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Labiana Health

All Key Metrics — Labiana Health